Nicox Extends Its Cash Flow Horizon Thanks to NCX 470

Nicox SA has announced a significant extension of its cash horizon, reaching €8.4 million as of August 31, 2026. This amount allows the company to finance its operations until early 2028. A potential milestone payment, linked to the approval of the NDA for the NCX 470 in the United States, could extend this horizon to 2029, and even beyond, thanks to future royalties.

The launch of NCX 470, subject to regulatory approval, is planned for the second half of 2027 in the United States. Nicox, a specialist in ophthalmology, is actively pursuing strategic discussions while maintaining its rigorous cost control measures.

Changes have also taken place within the leadership team, with Doug Hubatsch appointed Chief Scientific Advisor, leaving Siobhan Garbutt to take the lead in clinical development to guide the approval process and the evaluation of future opportunities.